TapImmune News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

18.05.17	TapImmune to Provide First Quarter 2017 Business Update Conference Call and Webcast (PR Newswire)
01.05.17	Richard Kenney, MD, FACP, Joins TapImmune to Lead the Clinical Development Program (PR Newswire)
28.04.17	TapImmune Announces Change in Management and Board of Directors (PR Newswire)
18.04.17	Positive News in the Fight Against Cancer Fuels Quest for More Good Tidings (PR Newswire)
06.04.17	Global Oncology Market Gains Ground, Driven by Innovative Cancer Treatment Therapies (PR Newswire)
23.03.17	Innovative Immunotherapies Emerging as the Cancer Treatments of the Future (PR Newswire)
23.03.17	Innovative Immunotherapies Emerging as the Cancer Treatments of the Future (PR Newswire)
22.03.17	TapImmune to Participate in Two Upcoming Investor and Industry Conferences (PR Newswire)
14.03.17	TapImmune Provides Year End 2016 Corporate and Clinical Update (PR Newswire)
14.03.17	TapImmune Announces Fully Funded Phase 2 Clinical Study of HER2-Targeted Vaccine in Early Breast Cancer (PR Newswire)
08.03.17	TapImmune to Host Inaugural Quarterly Business Update Conference Call and Webcast (PR Newswire)
21.02.17	Immunotherapy Companies Leading the Charge for Treating Cancer (PR Newswire)
15.02.17	TapImmune Advances TPIV 200 Phase 2 Triple-Negative Breast Cancer Trial After Favorable DSMB Safety Review (PR Newswire)
02.02.17	TapImmune Completes Scale-Up and GMP Manufacturing of TPIV 200 Vaccine to Supply Additional Phase 2 Clinical Trials (PR Newswire)
30.01.17	Life Sciences & Healthcare Investor Conference & Webinar: Nasdaq and OTCQX Companies Present February 2nd (PR Newswire)
30.01.17	TapImmune, Inc. to Webcast, Live, at VirtualInvestorConferences.com February 2 (PR Newswire)
10.01.17	TapImmune Launches Phase 2 Ovarian Cancer Trial In Platinum-Sensitive Patients (PR Newswire)
05.01.17	TapImmune To Present At Biotech Showcase 2017 (PR Newswire)
31.12.16	TapImmune: Year End 2016 Update (PR Newswire)
06.12.16	TapImmune To Present At The LD Micro IX Main Event, December 6-8, 2016 (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Swiss Re	133.55	4.50 %	K V
Swiss Life Hldg	693.60	0.93 %	K V
Zurich Insur Gr	552.80	0.91 %	K V
Kuehne+Nagel Int	206.60	0.78 %	K V
Sonova Hldg	294.00	0.58 %	K V
Sika	228.20	-1.04 %	K V
Part Grp Hldg	1’264.50	-1.56 %	K V
Geberit	538.20	-1.61 %	K V
Alcon	75.22	-1.75 %	K V
Lonza Grp	532.80	-2.81 %	K V